Sign up


Match Document Document Title
8142786 Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein  
The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
8138154 Biglycan and related therapeutics and methods of use  
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with...
8133496 Compositions and methods for diagnosing and treating urinary tract infections  
The present invention relates to methods and compositions for treating urinary tract infections. In particular, the present invention relates to vaccines and immune modulators for treating urinary...
8128935 DNA sequence and recombinant production of the grass pollen allergen Phl p 4  
The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention also covers fragments, new combinations of partial sequences and...
8129345 MUC1-IκB kinase complexes and their activities  
The disclosure provides methods of identifying and making compounds and pharmaceutical compositions containing the compounds that inhibit the interaction between MUC1 and an IKK. The disclosure...
8128936 Immunogenic compositions for Streptococcus pyogenes  
The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS...
8129344 Method of reducing cell death by administering a Sfrp polypeptide  
A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions.
8124099 Soluble CD83 proteins and use thereof for the treatment and prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells  
The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular...
8124097 Hybrid and chimeric polypeptides that regulate activation of complement  
A hybrid complement-regulating protein comprises a first functional unit of a first complement regulatory protein having complement regulating properties, a first spacer sequence of at least about...
8124105 Compositions, methods and kits relating to poxvirus subunit vaccines  
The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such...
8124055 Compositions and methods to control angiogenesis with cupredoxins  
The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that...
8124103 Influenza antigens, vaccine compositions, and related methods  
The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza...
8119139 Immunotherapy against several tumors including neuronal and brain tumors  
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present...
8114406 Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins  
The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consistin...
8114415 Method for producing temperature sensitive influenza A viruses  
Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid...
8114407 EphA2 T-cell epitopes and uses therefor  
EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative...
8114405 Cancer vaccine based on brother of regulator of imprinted sites molecule (BORIS)  
Polynucleotides encoding a nonfunctional mutant form of the Brother of Regulator of Imprinted Sites (BORIS) molecule, nonfunctional mutated BORIS protein, polypeptide or peptide and modified...
8114410 Composition and methods for the inhibition of membrane fusion by paramyxoviruses  
Fusion of the membrane of enveloped viruses with the plasma membrane of a receptive host cell is a prerequisite for viral entry and infection and an essential step in the life cycle of all...
8110546 VEGF antagonist formulations  
Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a...
8110662 Antibody directed to protein involved in maintaining differentiation of smooth muscle cells  
A cDNA fragment participating in the maintenance of smooth muscle differentiation was isolated using a culture system of chicken gizzard smooth muscle cells, the differential display method and the...
8110657 Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein  
Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the...
8110198 Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics  
The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies...
8110200 Fusion proteins of Mycobacterium tuberculosis  
The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The...
8110201 Fusion proteins of mycobacterium tuberculosis  
The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The...
8105602 Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof  
The present invention relates to antibodies, and antigen-binding fragments thereof, specific for urokinase-type plasminogen activator receptor (uPAR) and uses thereof for the treatment or...
8105604 WT1 modified peptide  
The present invention discloses a cancer antigen peptide comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), a cancer vaccine having this for its...
8106015 Method for enhancing immune response with peptide  
An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β ...
8105797 Diagnostic test  
The invention provides a method of diagnosing Mycobacterium tuberculosis infection in a human, or of determining whether a human has been exposed to Mycobacterium tuberculosis, comprising: (i)...
8105603 Polypeptides that bind APRIL  
The present invention relates to polypeptides that inhibit APRIL and/or BAFF binding to BCMA, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The...
8105605 Allergen formulation  
Provided is a pharmaceutical composition comprising tyrosine, an optionally modified allergen, and 3-DMPL, which is useful in the prevention and treatment of allergies.
8105612 Serum resistance factors of gram positive bacteria  
A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.
8101192 Methods for producing an immune response to tuberculosis  
Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional...
8101193 Tuberculosis vaccines comprising antigens expressed during the latent infection phase  
The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M....
8101186 Peptides that block the binding of IgG to FcRn  
The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods...
8101367 Antibodies specific to antigens of Bartonella henselae and use of these antigens in immunoassays  
Disclosed are antibodies that bind to the antigenic proteins GroES, RpIL, GroEL, SodB, UbiG, the ABC transporter, and an expressed antigenic protein of unknown function (the “BepA” protein) of Bar...
8101190 Method for diagnosing staphylococcal infections  
The present invention relates to a method for determining if an individual is infected by a staphylococcus bacterium, comprising: determining if antibodies directed against at least 2 proteins...
RE43140 Immunoregulator  
The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory...
8101187 Secreted Streptococcus pneumoniae proteins  
Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.
8097252 Methods and compositions for administering therapeutic and diagnostic agents  
Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
8097257 MAGE3 polypeptides  
The present invention relates to novel MAGE3 polypeptides, including a fragment of MAGE3 fused to an immunological fusion partner, and compositions thereof.
8097256 Cancer vaccines and vaccination methods  
Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
8097587 IGF-I protein variants for treating IGFBP-1-related disorders  
IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder...
8093008 Characterization of granulocytic ehrlichia and methods of use  
The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1,...
8093046 CVN-12p1: a recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions  
The invention provides a recombinant multi-functional chimera of CVN and 12p1. Chimeras of CVN and 12p1 present a model for targeting gp120 at two discrete sites, by two different modes of...
8092805 Dual inhibitors of HIV-1 gp-120 interactions  
Compounds, which inhibit the binding of gp120 to CD4 as well as 17b and methods for their use in inhibiting the HIV fusion process, are provided.
8092807 Modified leukocyte Ig-like receptor family members (LIRs) with increased affinity for class 1 MHC and their uses in modulating T-cell activation  
The present invention provides polypeptides having the property of binding to a given Class I pMHC CHARACTERISED IN THAT said polypeptide has a KD for the said given Class I pMHC of less than or...
8092806 Chimeric proteins, their preparation and pharmaceutical compositions containing them  
The present invention relates to a chimeric protein comprising a cell-targeting agent and a Yersinia outer protein, connected by a translocating polypeptide. The invention further relates to the...
8088389 Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases  
Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease,...
8088388 Stabilized synthetic immunogen delivery system  
The present invention provides an immunostimulatory complex specifically adapted to act as adjuvant and as a peptide immunogen stabilizer. The immunostimulatory complex comprises a CpG...
8088390 Methods for the early diagnosis of ovarian cancer  
The present invention discloses the protease stratum corneum chymotryptic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune...